Targeting ECM disrupts cancer progression FA Venning, L Wullkopf, JT Erler Frontiers in oncology 5, 224, 2015 | 284 | 2015 |
ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix AE Mayorca-Guiliani, CD Madsen, TR Cox, ER Horton, FA Venning, ... Nature medicine 23 (7), 890-898, 2017 | 173 | 2017 |
Hypoxia and loss of PHD 2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis CD Madsen, JT Pedersen, FA Venning, LB Singh, E Moeendarbary, ... EMBO reports 16 (10), 1394-1408, 2015 | 151 | 2015 |
Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer FA Venning, KW Zornhagen, L Wullkopf, J Sjölund, C Rodriguez-Cupello, ... Journal of Experimental & Clinical Cancer Research 40 (1), 175, 2021 | 30 | 2021 |
The carcinogenic agent azoxymethane (AOM) enhances early inflammation-induced colon crypt pathology FA Venning, MH Claesson, H Kissow J Cancer Sci Ther 5 (11), 377-383, 2013 | 10 | 2013 |
Targeting ECM disrupts cancer progression. Front Oncol 5: 224 FA Venning, L Wullkopf, JT Erler | 9 | 2015 |
Enteroantigen (eAg)‐binding B lymphocytes in the mouse–phenotype, distribution, function and eAg‐specific antibody secretion FA Venning, ML Trempenau, E Schmidt, MH Claesson Apmis 122 (7), 616-627, 2014 | 4 | 2014 |
Heterogeneity of cancer-associated fibroblasts: Metastatic potential and time determine CAF population composition FA Venning, KW Zornhagen, T Thurison, CD Madsen, JT Erler INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 99 (6), A36-A36, 2018 | | 2018 |